Project Grant R01CA308165
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $676K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cold Spring Harbor, NY 11724, USA
Similar Awards
- The National Cancer Institute awarded Cold Spring Harbor Laboratory $770,911 under the Cancer Biology Research program (CFDA 93.396) on July 1, 2026, to define the role of sphingolipid synthesis in anti-tumor immunity. The project investigates how alterations in lipid metabolism, particularly sphingolipid synthesis catalyzed by serine palmitoyl transferase (SPT), enable cancer cells to evade immune attack in the tumor microenvironment. Preliminary in vivo genetic screens in KRAS-mutant mouse...
- The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai $683,256 on May 22, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop and validate a human-mouse platform for patient stratification and therapeutic target discovery in glioblastoma. The recipient will integrate single-cell RNA-sequencing data from 199 glioblastoma patients with spatial transcriptomics technologies to dissect tumor microenvironment cell composition, spatial tissue organization,...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded The Trustees of Columbia University in the City of New York $702,132 on June 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct multiplex single-cell chemical genomics screening aimed at identifying small molecule modulators of tumor cell-intrinsic immunogenicity in glioblastoma. The research program will expose glioblastoma neurosphere models to 3,792 small...
- The National Cancer Institute awarded Cold Spring Harbor Laboratory $704,182 under the Cancer Biology Research program (CFDA 93.396) on June 16, 2026, to dissect non-mutational mechanisms driving benign-to-malignant transition in colorectal cancer. The project uses a novel mouse model that stepwise acquires mutations mirroring human colorectal cancer progression—starting with APC knockout to initiate benign polyps, then inducing KRAS G12V and TP53 loss in rare cells within established polyps...
- The National Cancer Institute awarded Massachusetts General Hospital $652,908 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research restoring dendritic-cell-derived immune signaling to reinvigorate T cells in glioblastoma. The project addresses the failure of immunotherapy to produce durable benefit in glioblastoma multiforme, the most aggressive primary brain tumor in adults, where standard treatments—surgery, radiation, and temozolomide—extend...
- The National Institutes of Health National Cancer Institute awarded Massachusetts General Hospital (The General Hospital Corporation) $707,798 on April 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to determine mechanisms of heterogeneous treatment response in glioblastoma using multi-omic and multi-organ approaches. The research identifies transcriptional, genetic, neuronal, and immunological factors influencing glioblastoma formation, progression, and treatment response,...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded Albert Einstein College of Medicine $431,970 under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2026. The recipient will conduct research into epigenetic regulation of glioblastoma stem-like cells, specifically exploring how the arginine methyltransferase CARM1 controls NGFR and NTRK signaling pathways. The work encompasses two primary aims: testing...
- The National Institutes of Health National Cancer Institute awarded Cold Spring Harbor Laboratory $793,679 on August 6, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop whole-body redox maps for metastatic cancer therapy. The project uses protein degradation-based sensing to visualize oxidative stress in vivo across animal models of prostate cancer. The work generates two complementary, immune-competent mouse models—OXIGEM and ROXYCAP—that reveal cellular redox states...
- The National Cancer Institute, within the Department of Health and Human Services National Institutes of Health, awarded Yale University $488,162 on August 19, 2026, under the Cancer Biology Research program (CFDA 93.396) to catalog disease processes over the lifespan of glioma using the International Glioma Longitudinal Analysis (GLASS) Consortium dataset. The award funds analysis of tumor heterogeneity and its evolution in response to treatment across the GLASS database, which since 2014 has...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $745,471 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate hematopoietic stem cell-encoded anti-tumor immunity mechanisms in response to intravesical bacillus Calmette-Guerin (BCG) therapy for non-muscle invasive bladder cancer. The research examines how BCG induces long-term tumor-specific T cell immunity and explores upstream mechanisms by which BCG stimulates...